Skip to main content
. Author manuscript; available in PMC: 2019 Aug 28.
Published in final edited form as: J Control Release. 2018 Jun 5;284:171–178. doi: 10.1016/j.jconrel.2018.06.002

Figure 4. Pre-existing concentrations of APA measured in the majority of the population is insufficient to impact the PK of PEG-uricase.

Figure 4

(A) Frequency of IgG APA concentrations measured in a sampling of the general public, reproduced from [20]. Dashed line represents the lower limit of detection. (B) AUC of pegloticase at different circulating APA concentrations, estimated by the mPBPK model. Y-axis values are percentages of AUC relative to predicted AUC with no APA. (C) Sweep of predicted AUC of pegloticase administered to simulated human patients with varying pre-existing APA, without the induction of further APA production.